Staphylococcal spp. are notorious for causing biofilm-related device-associated infections, leading to tens of thousands of deaths per year. In this paper, we review quorum sensing inhibitors as potential therapeutics for even the most persistent infections. The animal models reviewed are subcutaneous graft, central venous catheter (CVC), ureteral stent and wound models, and a wound case study. The therapeutic approaches reviewed are the use of RNAIII inhibiting peptide (RIP) and its non-peptide analog. These have been shown to prevent or treat infections caused by any staphylococcal strain tested, including antibiotic-resistant strains like CA-MRSA USA300. (Int J Artif Organs 2008; 31: 761–70)
DavisJ.S.Management of bone and joint infections due to Staphylococcus aureus. Intern Med J2005; 35(Suppl 2): S79–96.
6.
SteinA., BatailleJ.F., DrancourtM.Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother1998; 42: 3086–91.
7.
StewartP.S., CostertonJ.W.Antibiotic resistance of bacteria in biofilms. Lancet2001; 358: 135–8.
8.
MillerM.B., BasslerB.L.Quorum sensing in bacteria. Annu Rev Microbiol2001; 55: 165–99.
9.
BalabanN., NovickR.P.Autocrine regulation of toxin synthesis by Staphylococcus aureus. Proc Natl Acad Sci U S A1995; 92: 1619–23.
10.
BalabanN., GoldkornT., NhanR.T.Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science1998; 280: 438–40.
11.
KoremM., SheoranA.S., GovY., TziporiS., BorovokI., BalabanN.Characterization of RAP, a quorum sensing activator of Staphylococcus aureus. FEMS Microbiol Lett2003; 223: 167–75.
12.
YangG., ChengH., LiuC.Inhibition of Staphylococcus aureus pathogenesis in vitro and in vivo by RAP-binding peptides. Peptides2003; 24: 1823–8.
13.
HanY.H., KimY.G., KimD.Y., HaS.C., LokanathN.K., KimK.K.The target of RNAIII-activating protein (TRAP) from Staphylococcus aureus: purification, crystallization and preliminary X-ray analysis. Biochim Biophys Acta2005; 1748: 134–6.
14.
MichelA., AgererF., HauckC.R.Global regulatory impact of ClpP protease of Staphylococcus aureus on regulons involved in virulence, oxidative stress response, autolysis, and DNA repair. J Bacteriol2006; 188: 5783–96.
15.
WangC., LiM., DongD.Role of ClpP in biofilm formation and virulence of Staphylococcus epidermidis. Microbes Infect2007; 9: 1376–83.
16.
FreesD., SorensenK, and IngmerH.Global virulence regulation in Staphylococcus aureus: pinpointing the roles of ClpP and ClpX in the sar/agr regulatory network. Infect Immun2005; 73: 8100–8.
17.
FreesD., ChastanetA., QaziS.Clp ATPases are required for stress tolerance, intracellular replication and biofilm formation in Staphylococcus aureus. Mol Microbiol2004; 54: 1445–62.
18.
FreesD., QaziS.N., HillP.J., IngmerH.Alternative roles of ClpX and ClpP in Staphylococcus aureus stress tolerance and virulence. Mol Microbiol2003; 48: 1565–78.
19.
DesiereF., LucchiniS., BrussowH.Comparative sequence analysis of the DNA packaging, head, and tail morphogenesis modules in the temperate cos-site Streptococcus thermophilus bacteriophage Sfi21. Virology1999; 260: 244–53.
20.
DerreI., RapoportG., MsadekT.CtsR, a novel regulator of stress and heat shock response, controls clp and molecular chaperone gene expression in gram-positive bacteria. Mol Microbiol1999; 31: 117–31.
21.
LinaG., JarraudS., JiG.Transmembrane topology and histidine protein kinase activity of AgrC, the agr signal receptor in Staphylococcus aureus. Mol Microbiol1998; 28: 655–62.
22.
GustafssonE., NilssonP., KarlssonS., ArvidsonS.Characterizing the Dynamics of the Quorum-Sensing System in Staphylococcus aureus. J Mol Microbiol Biotechnol2004; 8: 232–42.
23.
LyonG.J., WrightJ.S., MuirT.W., NovickR.P.Key determinants of receptor activation in the agr autoinducing peptides of Staphylococcus aureus. Biochemistry2002; 41: 10095–104.
24.
ParkJ., JagasiaR., KaufmannG.F.Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol2007; 14: 1119–27.
25.
GomesA.R., VingaS., ZavolanM., de LencastreH.Analysis of the genetic variability of virulence-related loci in epidemic clones of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother2005; 49: 366–79.
26.
YangG., GaoY., DongJ.A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection. Vaccine2006; 24: 1117–23.
27.
BalabanN., GoldkornT., GovY.Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP). J Biol Chem2001; 276: 2658–67.
28.
YangG., GaoY., DongJ.A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections. J Biol Chem2005; 280: 27431–5.
29.
GovY., BitlerA., Dell'AcquaG., TorresJ.V., BalabanN.RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides2001; 22: 1609–20.
30.
AbrahamW.R.Controlling biofilms of gram-positive pathogenic bacteria. Curr Med Chem2006; 13: 1509–24.
31.
Vieira-da-MottaO., RibeiroP.D., Dias da SilvaW., Medina-AcostaE.RNAIII inhibiting peptide (RIP) inhibits agr-regulated toxin production. Peptides2001; 22: 1621–7.
32.
KiranM.D., AdikesavanN.V., CirioniO.Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening. Mol Pharmacol2008; 73: 1578–86.
33.
BalabanN., CirioniO., GiacomettiA.Treatment of Staphylococcus aureus biofilm infection by the quorumsensing inhibitor RIP. Antimicrob Agents Chemother2007; 51: 2226–9.
34.
BalabanN., CollinsL.V., CullorJ.S.Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides2000; 21: 1301–11.
35.
BalabanN., GiacomettiA., CirioniO.Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis2003; 187: 625–30.
36.
BalabanN., GovY., GiacomettiA.A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother2004; 48: 2544–50.
37.
BalabanN., StoodleyP., FuxC.A., WilsonS., CostertonJ.W., Dell'AcquaG.Prevention of staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP. Clin Orthop Relat Res2005; 437: 48–54.
38.
CirioniO., GhiselliR., MinardiD.RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection. Antimicrob Agents Chemother2007; 51: 4518–20.
39.
CirioniO., GiacomettiA., GhiselliR.Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides. Circulation2003; 108: 767–71.
40.
CirioniO., GiacomettiA., GhiselliR.RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. J Infect Dis2006; 193: 180–6.
41.
Dell'AcquaG., GiacomettiA., CirioniO.Suppression of drug-resistant Staphylococcal Infections by the quorumsensing inhibitor RNAIII-inhibiting peptide. J Infect Dis2004; 190: 318–20.
42.
DomenicoP., GurzendaE., GiacomettiA.BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. Peptides2004; 25: 2047–53.
43.
Anguita-AlonsoP., GiacomettiA., CirioniO.RNAIII-inhibiting-peptide-loaded polymethyl methacrylate prevents in vivo Staphylococcus aureus biofilm formation. Antimicrob Agents Chemother2007; 51: 2594–6.
44.
GiacomettiA., CirioniO., GhiselliR.RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides2005; 26: 169–75.
45.
GiacomettiA., CirioniO., GovY.RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob Agents Chemother2003; 47: 1979–83.
46.
SimonettiO., CirioniO., GhiselliR.Rip Enhances Healing of Wounds Infected with Methicillin Resistant Staphylococcus aureus. Antimicrob Agents Chemother2008; 52: 2205–11.
Boyle-VavraS., DaumR.S.Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest2007; 87: 3–9.
DowdS.E., SunY., SecorP.R.Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol2008; 8: 43.
AtelaI., CollP., RelloJ.Serial surveillance cultures of skin and catheter hub specimens from critically ill patients with central venous catheters: molecular epidemiology of infection and implications for clinical management and research. J Clin Microbiol1997; 35: 1784–90.
56.
CostertonJ.W., MontanaroL., ArciolaC.R.Biofilm in implant infections: its production and regulation. Int J Artif Organs2005; 28: 1062–8.
57.
WolcottR.Control of biofilm infections by signal manipulation. BalabanN., ed. Springer Series on Biofilms, Vol. 2. Berlin: Springer-Verlag; 2008.
